FDA Approves Sanofi's Multiple Myeloma Drug
The U.S. Food and Drug Administration (FDA) announced that it has approved Sanofi's (NASDAQ: SNY) new drug for patients with reoccurring multiple myeloma. Sarclisa (also known as isatuximab) is a treatment that promotes tumor cell death by targeting a specific protein type found on the surface of white blood cells.
The agency approved Sarclisa to be used as a drug combo alongside Bristol-Myers Squibb's Pomalyst (also known as pomalidomide) and a steroid medication known as dexamethasone. Adult patients who have had at least two previous treatments for multiple myeloma but have had the condition return are eligible for this treatment.
Image source: Getty Images.
Source Fool.com
